Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 22, 2026Journal of Neurology Neurosurgery & Psychiatry

Discontinuation of ocrelizumab in multiple sclerosis: reoccurrence of disease activity

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFranz Felix KonenFAFranziska AxhausenSWStephanie Wolff

Discussion

Loading...

Member takes

Overview

Cohort study examines disease activity recurrence in multiple sclerosis following ocrelizumab discontinuation, suggesting careful monitoring post-treatment.

Key Points

  • This research aims to understand the effects of stopping ocrelizumab on disease activity in people with multiple sclerosis.
  • Conducted a prospective observational cohort study at two German MS centers.
  • Included pwMS who received ocrelizumab for at least 12 months without inflammatory activity.
  • Performed propensity score matching analysis to compare continuation and discontinuation groups.
  • Monitored time to combined inflammatory activity and progression independent of relapse activity.
  • No significant difference in disease activity recurrence between discontinuers and continuers.
  • Stable disease activity noted beyond 24 months post-discontinuation with no statistical significance.
  • ROC analysis indicated no additional benefit of treatment after 29-30 months, with increased risk of reactivation after 32 months off-treatment.

Cite This Study

Konen et al. (2026) studied this question.

synapsesocial.com/papers/6971be2c642b1836717e2cb7https://doi.org/10.1136/jnnp-2025-337944
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension2023 · 31 citations
  2. 2Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls2025
  3. 3Long‐Term Clinical and Psychological Efficacy and Safety of Ocrelizumab in People With Multiple Sclerosis: A Real‐World Longitudinal Study2026 · 1 citations
  4. 4Ocrelizumab Discontinuation vs. Continuation After Safety Events:Comparative Insights from MSBase2026
  5. 5CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany2025 · 4 citations